🔗 Share this article

Given that the United States undertakes historic changes to its immunization schedules, a particular individual has emerged unexpectedly: Høeg, a US-based sports physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccinations in the pandemic and has concentrated on possible deaths after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Schedule

Public health authorities planned to unveil sweeping revisions to the childhood immunization program in December, aligning the US with the Danish national calendar, it is understood – a major change that would put the US out of alignment with many the world with no evidence for benefit. The planned update has been pushed back until the new year.

Instead of Vinay Prasad, Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s CDER, the fifth individual to lead the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment may indicate a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for halting some childhood shot schedules in the US so as to align more like Denmark's approach, a nation with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Concerns Over Expertise

Høeg has no obvious experience in drug development, approval processes or management, which has been typical for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in leading a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of CBER would “understand legal statutes and the research of medication creation”, said Dr. Janet Woodcock. “Clearly, she lacks the type of experience that former directors who headed CBER have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“The public just pays attention on the new drug program, but the generic drug division authorizes a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and more, and every single one must be managed,” she noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the position, which oversees in excess of 5,000 employees. “It is a enormous administrative position, if you execute it properly,” the former official said.

Agency Reaction and Contentious Programs

When asked about questions about Høeg’s credentials and whether this appointment indicates more teamwork among agency officials on immunizations, a representative stated that the “questions are based on flawed presumptions”.

“This background is consistent with the functions of her role,” the spokesperson stated, noting the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious one-day drug-approval program that allegedly worried her former heads. “How are these drugs being selected for this expedited pathway? Who takes the calls?” Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he said, “the agency appears to be shifting towards laxer oversight of pharmaceuticals, except for vaccines.”

Established Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if concerning, history, Howard observe. She published a analysis using unconfirmed volunteer-provided data to determine the rate of heart inflammation following Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the current federal leadership included revising regulations for recently developed shots and halting “optional” immunizations, she remarked after the election on a podcast. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from getting Covid vaccinations.

“She is an complete ideologue who begins with her conclusions and reverse-engineers to fit the science in a highly misleading, fraudulent manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|